ACROBiosystems

ACROBiosystems

Address
1 Innovation Way
Newark
DE, 19711
United States
Phone: +1 (800) 810 0816
Visit Website Request Information/Quote Download PDF Copy

 

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines, and diagnostics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process.

ACROBiosystems' catalog includes a comprehensive list of disease-associated biomarkers and drug targets from humans to other common species. All of our products are produced with high quality and batch-to-batch consistency to satisfy the rigorous standards of pharmaceutical research and development.

ACROBiosystems continue to grow and adapt to bring more value to our clients by providing more technical resources and custom services, promoting training and communication opportunities, initiating collaborations in the bio-industry community, and facilitating transactions in the dynamic global and each niche market.

ACROBiosystems makes donations to BEI Resources, accelerating the process of attacking SARS-CoV-2 variants globally

ACROBiosystems makes donations to BEI Resources, accelerating the process of attacking SARS-CoV-2 variants globally

Archived ACROBiosystems News

ACROBiosystems and the Fight Against COVID-19

ACROBiosystems and the Fight Against COVID-19
Antigens and Fc receptor proteins for biosimilar drug targeting

Antigens and Fc receptor proteins for biosimilar drug targeting
B-cell maturation antigen for plasma cell cancer therapy

B-cell maturation antigen for plasma cell cancer therapy
Biotinylated proteins for use in research

Biotinylated proteins for use in research
CAR-specific monoclonal FMC63 antibodies for CD19 CAR expression evaluation

CAR-specific monoclonal FMC63 antibodies for CD19 CAR expression evaluation
CD19 proteins: Therapeutic targets for B-cell cancers

CD19 proteins: Therapeutic targets for B-cell cancers
CD20 from ACROBiosystems

CD20 from ACROBiosystems
CD3 proteins: Targets for bispecific antibodies

CD3 proteins: Targets for bispecific antibodies
Claudin18.2 proteins expressed from HEK293 cells

Claudin18.2 proteins expressed from HEK293 cells
Cynomolgus Siglec-15 / CD33L3 Protein, His Tag fromACROBiosystems

Cynomolgus Siglec-15 / CD33L3 Protein, His Tag fromACROBiosystems
Evaluating CAR expression with biotinylated, fluorescence-labeled, and unconjugated proteins

Evaluating CAR expression with biotinylated, fluorescence-labeled, and unconjugated proteins
Evaluation of CAR Expression - Protein Solutions

Evaluation of CAR Expression - Protein Solutions
Fc receptor proteins for research and development

Fc receptor proteins for research and development
Fluorescence-Activated Cell Sorting (FACS) - Immune Checkpoint Proteins

Fluorescence-Activated Cell Sorting (FACS) - Immune Checkpoint Proteins
Fluorescent-labeled proteins (FTIC and PE-labeled) for biological drug development

Fluorescent-labeled proteins (FTIC and PE-labeled) for biological drug development
Full-length CD20 membrane proteins for research and development

Full-length CD20 membrane proteins for research and development
High bioactivity proteins for antibody drug conjugate (ADC) development

High bioactivity proteins for antibody drug conjugate (ADC) development
High purity, high bioactivity immune checkpoint proteins

High purity, high bioactivity immune checkpoint proteins
Interleukin-2 (IL-2) receptors from ACROBiosystems

Interleukin-2 (IL-2) receptors from ACROBiosystems
Llama IgG Fc Fusion Proteins for Llama Immunization

Llama IgG Fc Fusion Proteins for Llama Immunization
Monoclonal Antibodies for Rituximab, Cetuximab and Adalimumab Molecules

Monoclonal Antibodies for Rituximab, Cetuximab and Adalimumab Molecules
Neutralizing antibody serologic assay kits for SARS-CoV-2 and its variants

Neutralizing antibody serologic assay kits for SARS-CoV-2 and its variants
SARS-CoV-2 emerging variants: Antigens, antibodies, ELISA kits, and more

SARS-CoV-2 emerging variants: Antigens, antibodies, ELISA kits, and more
SARS-CoV-2 related research products: Proteins, antibodies and more

SARS-CoV-2 related research products: Proteins, antibodies and more
SPR Validated Fc Receptor Proteins

SPR Validated Fc Receptor Proteins
Targeting the tumor microenvironment (TME) pathways with ACROBio

Targeting the tumor microenvironment (TME) pathways with ACROBio
Targets for bispecific antibodies

Targets for bispecific antibodies
Technology platforms for multi-pass transmembrane protein development

Technology platforms for multi-pass transmembrane protein development
A Cost-Effective, Efficient and Convenient Bead-Based Phagocytosis Assay

A Cost-Effective, Efficient and Convenient Bead-Based Phagocytosis Assay
Accelerating COVID-19 Neutralizing Antibody Screening

Accelerating COVID-19 Neutralizing Antibody Screening
ACROBiosystems Innovative Lab Capabilities

ACROBiosystems Innovative Lab Capabilities
An Emerging Immue Checkpoint Target: TIGIT

An Emerging Immue Checkpoint Target: TIGIT
Antibody drug development: Targeting CD20 and CD3

Antibody drug development: Targeting CD20 and CD3
Anti-Idiotypic Antibodies Overview

Anti-Idiotypic Antibodies Overview
Anti-idiotypic antibodies: How are they used in drug development?

Anti-idiotypic antibodies: How are they used in drug development?
Anti-tumor treatment with a Nanobody

Anti-tumor treatment with a Nanobody
Are Serological Tests Unreliable? Or the Protein Reagents?

Are Serological Tests Unreliable? Or the Protein Reagents?
Available SARS-CoV-2 Antigen Proteins for Testing

Available SARS-CoV-2 Antigen Proteins for Testing
Capabilities of a Recombinant Spike Protein Trimer

Capabilities of a Recombinant Spike Protein Trimer
CAR-T Therapy: Combating Cytokine Release Syndrome

CAR-T Therapy: Combating Cytokine Release Syndrome
CAR-T therapy: Grading and mitigating Cytokine Release Syndrome (CRS)

CAR-T therapy: Grading and mitigating Cytokine Release Syndrome (CRS)
CAR-T Therapy: Syndrome Released by Cytokine

CAR-T Therapy: Syndrome Released by Cytokine
Cell-Based Assays to Fight COVID-19

Cell-Based Assays to Fight COVID-19
Characterization and Identification of Neutralizing Antibodies Against COVID-19

Characterization and Identification of Neutralizing Antibodies Against COVID-19
Charting recent advances in PSMA-targeted therapy for prostate cancer

Charting recent advances in PSMA-targeted therapy for prostate cancer
Chimeric Antigen Receptor Expression Evaluation

Chimeric Antigen Receptor Expression Evaluation
Combating Parkinson’s disease, the second most common neurodegenerative disease

Combating Parkinson’s disease, the second most common neurodegenerative disease
Controlling a Tumor Microenvironment

Controlling a Tumor Microenvironment
COVID-19 and the Role of Neutralizing Antibodies (NAbs)

COVID-19 and the Role of Neutralizing Antibodies (NAbs)
COVID-19 Neutralizing Antibody Screening Tools

COVID-19 Neutralizing Antibody Screening Tools
COVID-19 vaccines: An overview

COVID-19 vaccines: An overview
COVID-19 Vaccines: Safety and Efficacy Evaluation

COVID-19 Vaccines: Safety and Efficacy Evaluation
COVID-19: Can Aerosolized Nanobodies be a Gamechanger?

COVID-19: Can Aerosolized Nanobodies be a Gamechanger?
COVID-19: Omicron recombinants, where could the next strain emerge?

COVID-19: Omicron recombinants, where could the next strain emerge?
D614G Mutation of COVID-19: What Does it Mean?

D614G Mutation of COVID-19: What Does it Mean?
Development of New Tools to Fight SARS-CoV-2

Development of New Tools to Fight SARS-CoV-2
Developments in the targeting of Claudin 6 in Antibody and CAR-T cell therapies

Developments in the targeting of Claudin 6 in Antibody and CAR-T cell therapies
Discovering a potent neutralizing antibody (NAb) for future COVID-19 VOCs and mutants

Discovering a potent neutralizing antibody (NAb) for future COVID-19 VOCs and mutants
Discussing major hypotheses of Alzheimer’s disease

Discussing major hypotheses of Alzheimer’s disease
Dual targeting of both LILRB and HLA-G for an effective anti-cancer immunotherapy combination

Dual targeting of both LILRB and HLA-G for an effective anti-cancer immunotherapy combination
Evaluating CAR Expression for CAR-T Cell Therapy

Evaluating CAR Expression for CAR-T Cell Therapy
Evaluating CD19 CAR expression levels in clinical trial and quality checks

Evaluating CD19 CAR expression levels in clinical trial and quality checks
Examining SSTR2 as a potential therapeutic target for cancer therapy

Examining SSTR2 as a potential therapeutic target for cancer therapy
Examining the potential of CXCR4 and CCR5 as therapeutic targets for cancer and HIV therapy

Examining the potential of CXCR4 and CCR5 as therapeutic targets for cancer and HIV therapy
Fc receptors: A classification and overview

Fc receptors: A classification and overview
FcRn and its role as a therapeutic target

FcRn and its role as a therapeutic target
FGL1 Protein Characterization for Cancer Detection

FGL1 Protein Characterization for Cancer Detection
G-Protein coupled receptors (GPCRs) and their role in targeted drug development

G-Protein coupled receptors (GPCRs) and their role in targeted drug development
Gram-level supply and production of Omicron antigens and antibodies

Gram-level supply and production of Omicron antigens and antibodies
High-Affinity CD19 for CAR-T Cell Therapy

High-Affinity CD19 for CAR-T Cell Therapy
How to select a development strategy for anti-idiotypic antibodies

How to select a development strategy for anti-idiotypic antibodies
Human CD20 Full-Length Proteins

Human CD20 Full-Length Proteins
Identification of a Bispecific Antibody with Bioactivity Analysis

Identification of a Bispecific Antibody with Bioactivity Analysis
Identifying and Studying COVID-19 Spike Protein Mutations on B.1.617

Identifying and Studying COVID-19 Spike Protein Mutations on B.1.617
IFN-γ: Targeted antibodies for detection and monitoring

IFN-γ: Targeted antibodies for detection and monitoring
Immune Checkpoint Protein Testing

Immune Checkpoint Protein Testing
Inactivated Virus Samples to Verify COVID-19 Anti-Nucleocapsid Antibodies

Inactivated Virus Samples to Verify COVID-19 Anti-Nucleocapsid Antibodies
Infectivity of SARS-CoV-2 with Spike Protein Mutations

Infectivity of SARS-CoV-2 with Spike Protein Mutations
Integrin-Associated Protein CD47 Leukocyte Surface Antigen

Integrin-Associated Protein CD47 Leukocyte Surface Antigen
Investigating SARS-CoV-2 Therapeutic Structure with SEC-MALS

Investigating SARS-CoV-2 Therapeutic Structure with SEC-MALS
Is a Successful COVID-19 Candidate Vaccine to Market within One Year Feasible?

Is a Successful COVID-19 Candidate Vaccine to Market within One Year Feasible?
Isolating SARS-CoV-2 Antibodies for Future Treatments

Isolating SARS-CoV-2 Antibodies for Future Treatments
Key Features of SPR-Verified Fc Receptor Proteins

Key Features of SPR-Verified Fc Receptor Proteins
Living with COVID-19: A reflection on the pandemic

Living with COVID-19: A reflection on the pandemic
Mass Spectrometry Analysis of Heavy-Labeled Proteins

Mass Spectrometry Analysis of Heavy-Labeled Proteins
Measuring Drug Concentration in Serum - Evaluating Assay Designs

Measuring Drug Concentration in Serum - Evaluating Assay Designs
Multiple Sclerosis: Examining the pathology, etiology, and potential therapeutic drugs

Multiple Sclerosis: Examining the pathology, etiology, and potential therapeutic drugs
N Protein in COVID-19 Diagnostic Kits

N Protein in COVID-19 Diagnostic Kits
N Protein Variants and Their Importance in Antibody Test and Design

N Protein Variants and Their Importance in Antibody Test and Design
N Terminal Domain of S1 Protein: Potential Target for Coronavirus

N Terminal Domain of S1 Protein: Potential Target for Coronavirus
Omicron-specific antibodies help with Omicron-based and polyvalent vaccine R&D

Omicron-specific antibodies help with Omicron-based and polyvalent vaccine R&D
Overview of ELISA Testing for COVID-19 Antibodies

Overview of ELISA Testing for COVID-19 Antibodies
Process of Antibody Drug Development with SPR&BLI Analytical Service

Process of Antibody Drug Development with SPR&BLI Analytical Service
Recombinant Protein Receptor Tyrosine Kinases ROR1 and ROR2

Recombinant Protein Receptor Tyrosine Kinases ROR1 and ROR2
Results of Pfizer COVID-19 mRNA Vaccine Phase 1/2 Study

Results of Pfizer COVID-19 mRNA Vaccine Phase 1/2 Study
Reviewing immunological breast cancer targets

Reviewing immunological breast cancer targets
SARS-CoV-2 Infection: Do You Know About the Antibody-Dependent Enhancement (ADE)?

SARS-CoV-2 Infection: Do You Know About the Antibody-Dependent Enhancement (ADE)?
SARS-CoV-2 S Protein Glycosylation

SARS-CoV-2 S Protein Glycosylation
SARS-CoV-2 Spike D614G Mutant is More Transmissible than Other Mutants

SARS-CoV-2 Spike D614G Mutant is More Transmissible than Other Mutants
Sensitive and Accurate Diagnostic Tests of COVID-19 with High-Quality SARS-CoV-2 Proteins

Sensitive and Accurate Diagnostic Tests of COVID-19 with High-Quality SARS-CoV-2 Proteins
Supporting Therapeutic Antibody Development with Fc Receptor Affinity Testing

Supporting Therapeutic Antibody Development with Fc Receptor Affinity Testing
T cell Immunoreceptor with lg and ITIM Domains Signaling Axis

T cell Immunoreceptor with lg and ITIM Domains Signaling Axis
Targeting CD38/CD3 in the immunotherapy of Multiple Myeloma

Targeting CD38/CD3 in the immunotherapy of Multiple Myeloma
Targeting DLL-3 for a variety of potential lung cancer therapies

Targeting DLL-3 for a variety of potential lung cancer therapies
Targeting Interleukin-6 (IL-6) to alleviate immune and inflammatory system dysfunction

Targeting Interleukin-6 (IL-6) to alleviate immune and inflammatory system dysfunction
Targeting Multiple Myeloma Using B-Cell Maturation Antigens

Targeting Multiple Myeloma Using B-Cell Maturation Antigens
Targets for Biosimilar Drugs

Targets for Biosimilar Drugs
The B.1.617 Variant of SARS-CoV-2 is Likely Behind the COVID-19 Surge in India

The B.1.617 Variant of SARS-CoV-2 is Likely Behind the COVID-19 Surge in India
The Immune Checkpoint Pathway - PD-1 Recombinant Protein Collection

The Immune Checkpoint Pathway - PD-1 Recombinant Protein Collection
The pathology and epidemiology of Amyotrophic Lateral Sclerosis (ALS)

The pathology and epidemiology of Amyotrophic Lateral Sclerosis (ALS)
The tumor microenvironment: A summary of components and important pathways

The tumor microenvironment: A summary of components and important pathways
The two strategies for FcRn mediated therapeutic mechanisms

The two strategies for FcRn mediated therapeutic mechanisms
Therapeutic Antibody Quantification in Serum Samples Using ELISA Assay Kits

Therapeutic Antibody Quantification in Serum Samples Using ELISA Assay Kits
Therapeutic strategies for brain tumors: An overview

Therapeutic strategies for brain tumors: An overview
Using Animal Models to Defeat COVID-19

Using Animal Models to Defeat COVID-19
Using combination therapy to overcome insufficient responses in programmed death ligand-1 (PD-1) inhibitors

Using combination therapy to overcome insufficient responses in programmed death ligand-1 (PD-1) inhibitors
Verifying S Protein in a Trimeric Form

Verifying S Protein in a Trimeric Form
What We Know About SARS-CoV-2 One Year Later: Part 1

What We Know About SARS-CoV-2 One Year Later: Part 1
What We Know About SARS-CoV-2 One Year Later: Part 2

What We Know About SARS-CoV-2 One Year Later: Part 2
What We Know About SARS-CoV-2 One Year Later: Part 3

What We Know About SARS-CoV-2 One Year Later: Part 3
What We Know About SARS-CoV-2 One Year Later: Part 4

What We Know About SARS-CoV-2 One Year Later: Part 4

More White Papers